Drug Trial Radar · NCT06593522
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
61
Actual
Start
Dec 26, 2024
Primary completion
Oct 31, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the study is to characterize safety and efficacy of 2 dose levels of anvumetostat by investigator, and to evaluate anvumetostat monotherapy efficacy by Blinded Independent Central Review (BICR).
Conditions
- MTAP-deleted NSCLC
Interventions
anvumetostatDrug
Film-coated tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response (OR) per RECIST 1.1Time frame: Up to 35 months
- Objective response (OR) Measured by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) and Assessed per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)Time frame: Up to 35 months
- Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 35 months
- Number of Participants Experiencing Events of Interest (EOIs)Time frame: Up to 35 months
- Maximum Concentration (Cmax) of anvumetostatTime frame: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
- Time to Cmax (Tmax) of anvumetostatTime frame: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
- Area Under The Concentration-time Curve (AUC) of anvumetostatTime frame: Cycle 1: Day 1 and Day 15 pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, and 6 hours post-dose; Cycle 2: Day 1 and Day 15 pre-dose; Cycles 3-5: Day 1 pre-dose
Locations
91 sites in 16 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
City of Hope Orange County Lennar Foundation Cancer Center
Duarte, California
Cedars-Sinai Medical Center
Los Angeles, California
Valkyrie Clinical Trials
Los Angeles, California
University of California Los Angeles
Los Angeles, California
Rocky Mountain Cancer Centers
Denver, Colorado
Eastern Connecticut Hematology and Oncology Associates
Norwich, Connecticut
Hartford HealthCare Cancer Institute - Manchester
Plainville, Connecticut
Medstar Georgetown University Hospital
Washington D.C., District of Columbia
Our Lady of the Lake Cancer Institute
Baton Rouge, Louisiana
Trinity Health Saint Joseph Mercy Ann Arbor
Ann Arbor, Michigan
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan
Sarah Cannon Research Institute Oncology Partners
Nashville, Tennessee
United States Oncology Regulatory Affairs Corporate Office
Nashville, Tennessee
Texas Oncology Central/South Texas
Austin, Texas
Sarah Cannon Research Institute
Dallas, Texas
Texas Oncology - Dallas Fort Worth
Dallas, Texas
US Oncology Research Investigational Products Center
Irving, Texas
Texas Oncology Northeast Texas
Tyler, Texas
Virginia Cancer Specialists PC
Fairfax, Virginia
GenesisCare -North Shore Oncology
St Leonards, New South Wales, Australia
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia
Mater Hospital Brisbane
South Brisbane, Queensland, Australia
Cancer Research South Australia
Adelaide, South Australia, Australia
Instituto de Educacao Pesquisa e Gestao em Saude
Rio de Janeiro, Brazil
Centro Paulista de Oncologia
São Paulo, Brazil
Núcleo de Oncologia da Bahia
Salvador, Estado de Bahia, Brazil
Liga Norte-Riograndense Contra O Cancer
Natal, Rio Grande do Norte, Brazil
Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, Brazil
Fundacao pio xII Barretos
Barretos, São Paulo, Brazil
Fund Faculdade Regional Med Sao Jose Rio Preto
São José do Rio Preto, São Paulo, Brazil
Instituto do Cancer Estado SP Icesp
São Paulo, São Paulo, Brazil
Fundacao Antonio Prudente - Hosp AC Camargo
São Paulo, São Paulo, Brazil
Cross Cancer Institute
Edmonton, Alberta, Canada
William Osler Health System - Brampton Civic Hospital
Brampton, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
McGill University Health Centre Glen Site
Montreal, Quebec, Canada
Beijing Cancer Hospital
Beijing, China
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.